Stock Analysis·← Pickers

EMBC

Embecta Corp.

Embecta Corp. (EMBC) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 43.4, with 0/3 trend checks passing.

Price
$3.22
2026-07-16
Trend score
0/3
Downtrend
RSI (14)
43.4
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

EMBC with MA50 and MA200

15.3112.219.116.002.9007/3110/2401/2204/1707/15
EMBC2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$3.39-4.93% vs price
MA200
$9.46-65.97% vs price
RSI (14)
43.4Neutral zone
MACD Signal
BullishMomentum above signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for EMBC

Embecta Corp. (EMBC) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $3.22, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 4.9% and below the 200-day moving average by 66.0%.

Momentum and stretch context

EMBC currently has an RSI reading of 43.4, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.

What traders may watch next

For traders reviewing EMBC next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.

Company profile

About Embecta Corp.

Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Devdatt Kurdikar
Employees
1,850
Market cap
$191.0M
Beta
0.81
52-week range
$2.77 – $15.55
Dividend
Yes · $0.46
Exchange
NASDAQ
Country
US
IPO date
22 Mar 2022
ISIN
US29082K1051
CUSIP
29082K105
Company profile data from Financial Modeling Prep. EMBC listed on NASDAQ.
Share dilution

EMBC shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Dec 2020Mar 2026
Shares outstanding (latest)
58.3M
Since Dec 2020
+2.3%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. EMBC22 data points from Dec 2020 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about EMBC

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.